Sanofi - pressmeddelanden

Sol + värme + vår = pollensäsong!

sanofi-aventis — Mon, 06 May 2013 11:41:47 +0200

Pollensäsongen blir längre och längre samtidigt som antalet pollenallergiker växer stadigt. Bara i Sverige lider uppskattningsvis 1 150 000 personer av pollenallergi. Trots detta finns det idag ett stort kunskapsglapp kring pollenallergi.

Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study

sanofi-aventis — Thu, 25 Apr 2013 11:41:48 +0200

Sanofi and its subsidiary Genzyme announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The trial was designed to assess whether early initiation of AUBAGIO (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome can prevent or delay conversion to clinically definite multiple sclerosis (CDMS).

Sanofi and PATH announce the Launch of Large-scale Production of Semisynthetic Artemisinin against Malaria

sanofi-aventis — Fri, 12 Apr 2013 09:36:16 +0200

Paris, France, and South San Francisco, California - April 11, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and PATH’s Drug Development program, established through an affiliation with OneWorld Health, today announced the launch of the large-scale production line of semisynthetic artemisinin at Sanofi’s Garessio site in Italy.

Sanofi får europeiskt godkännande för ZALTRAP (aflibercept) för behandling av metastaserad kolorektal cancer

sanofi-aventis — Tue, 05 Feb 2013 09:21:00 +0100

Sanofi meddelar idag att de erhållit ett europeiskt godkännande av aflibercept 25 mg/ml för behandling av metastaserad kolorektal cancer. Aflibercept, som i Sverige kommer att marknadsföras under namnet ZALTRAP, ges som andra linjens behandling i kombination med FOLFIRI. Kombinationen har i studier visat signifikant förlängd total överlevnad hos patienter med metastaserad kolorektalcancer.

Lyxumia® (lixisenatid) får europeiskt godkännande för behandling av typ 2-diabetes

sanofi-aventis — Mon, 04 Feb 2013 08:46:00 +0100

Sanofi lanserar ny behandling: den första prandiella GLP-1 receptoragonisten, som tas en gång per dag i samband med måltid

Sanofi President, Global Operations, to retire

sanofi-aventis — Tue, 18 Dec 2012 10:00:00 +0100

Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that Hanspeter Spek, President, Global Operations, will retire from his current role in mid-2013. A succession plan will be announced in due course.

Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting

sanofi-aventis — Mon, 03 Dec 2012 10:24:00 +0100

Sanofi announced today that new research spanning the company’s marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012.

Sanofi Ranks Third on the Access to Medicine Foundation’s 2012 ATM Index

sanofi-aventis — Wed, 28 Nov 2012 13:46:35 +0100

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index) created by the Access to Medicine Foundation, an international non-profit organization dedicated to improving access to medicine to societies in need.

Sanofi får positivt utlåtande från CHMP för Lyxumia® (lixisenatid) för behandling av vuxna med typ 2-diabetes

sanofi-aventis — Mon, 19 Nov 2012 14:12:53 +0100

Sanofi meddelade idag att kommittén för humanläkemedel (CHMP) vid Europeiska läkemedelsmyndigheten (EMA) har utfärdat ett positivt yttrande där man rekommenderar godkännande av Lyxumia ® (lixisenatid) en gång dagligen för behandling av vuxna med typ 2-diabetes för att uppnå glykemisk kontroll i kombination med orala glukossänkande läkemedel och/eller basinsulin.

Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes

sanofi-aventis — Thu, 15 Nov 2012 15:45:48 +0100

Sanofi and T1D Exchange, a non-profit organization focused on type 1 diabetes, announced today on World Diabetes Day that they will collaborate on the TEENs registry study. The aim of the study is to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes.

Att leva med förmaksflimmer

sanofi-aventis — Fri, 09 Nov 2012 08:30:00 +0100

Hjärt- och Lungsjukas Riksförbund har tillsammans med Sanofi producerat Flimmerrapporten som presenteras idag. Omkring 210 000 svenskar beräknas lida av förmaksflimmer. Risken att få sjukdomen ökar med åldern och var fjärde person över 40 år förväntas drabbas av förmaksflimmer någon gång i livet.

Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The Lancet

sanofi-aventis — Thu, 01 Nov 2012 15:44:57 +0100

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the publication of results from the LEMTRADA™ (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis (MS) in the November 1, 2012, online issue of The Lancet.

Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine

sanofi-aventis — Thu, 01 Nov 2012 10:13:13 +0100

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine.

Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability

sanofi-aventis — Fri, 12 Oct 2012 16:41:58 +0200

Sanofi and its subsidiary Genzyme announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Genzyme to Present New Data from AUBAGIO® and LEMTRADATM Clinical Development Programs at ECTRIMS

sanofi-aventis — Tue, 09 Oct 2012 15:37:20 +0200

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO® (teriflunomide) and LEMTRADA TM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

Journal of Clinical Oncology Publishes Phase III Results of ZALTRAP® (aflibercept) VELOUR Study in Previously Treated Metastatic Colorectal Cancer

sanofi-aventis — Mon, 08 Oct 2012 17:25:05 +0200

Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).

New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population

sanofi-aventis — Fri, 05 Oct 2012 13:27:32 +0200

Paris, France – October 5, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results from the landmark ORIGIN trial showing treatment with Lantus® was approximately 3-fold more likely to achieve and maintain target glycemic levels, defined as HbA1C < 6.5% in this analysis, vs. standard care in individuals with pre-diabetes or early type 2 diabetes at high cardiovascular risk.

Sanofi to Acquire Genfar S.A., a Leader in Pharmaceutical Medicines in Colombia

sanofi-aventis — Wed, 03 Oct 2012 10:06:06 +0200

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has signed an agreement to acquire Genfar S.A., a leading pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will become a market leader in Colombia and expand its portfolio of affordable pharmaceuticals in Latin America.

Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement

sanofi-aventis — Wed, 03 Oct 2012 10:01:15 +0200

Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint

sanofi-aventis — Tue, 02 Oct 2012 15:49:50 +0200

Paris, France - October 2, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that ENGAGE, the first Phase 3 trial of its investigational oral therapy, eliglustat tartrate, in previously untreated patients with Gaucher disease type 1, met its primary endpoint.